Código 3003 (Harmonized System 2012 by 4 digits)
2024: US$128M, Total Trade Exchange
2024: US$10.3M, International Sales
2024: US$118M, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail was US$128M.
In 2024, the states with the most international sales in Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were Ciudad de México (US$3.81M), Jalisco (US$398k), Guanajuato (US$174k), and Estado de México (US$4.26k).
The states with the most international purchases in 2024 were Ciudad de México (US$51.5M), Jalisco (US$33.2M), Estado de México (US$26.6M), Querétaro (US$2.4M), and Coahuila de Zaragoza (US$2.22M).
In 2024, the main commercial destinations of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were United States (US$1.49M), India (US$1.35M), Morocco (US$454k), Brazil (US$203k), and Panama (US$191k).
The main commercial origins of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail in 2024 were India (US$34.3M), China (US$27.2M), United States (US$15.1M), France (US$9.82M), and Germany (US$8.2M).
In the global context, the main exporting countries of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail in 2022 were United States (US$1.4B), Portugal (US$1.23B), and Israel (US$1.2B). In the same year, the main importing countries of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were United States (US$1.36B), United Kingdom (US$1.31B), and Canada (US$881M).
US$128M, Total Trade Exchange (2024)
In 2024, the total trade exchange of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail in Mexico (including international purchases and sales) was US$128M.
The visualizations show the net balance of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
December, 2024
In December 2024, international sales of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were US$1.14M, while international purchases reached US$6.81M. The above results in a trade balance of -US$5.67M.
2024-Q4: US$897k, International Sales
The visualization shows the quarterly concentration of international sales of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail at state level.
In the fourth quarter of 2024, international sales were US$897k, being the states with the most sales Ciudad de México (US$897k).
Ciudad de México: US$3.81M, State with the Most International Sales (2024)
United States: US$1.49M, Main commercial destination (2024)
In 2024, the states with the highest international sales in Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were Ciudad de México (US$3.81M), Jalisco (US$398k), Guanajuato (US$174k), and Estado de México (US$4.26k).
In 2024, the countries with the most international purchases from Mexico were United States (US$1.49M), India (US$1.35M), Morocco (US$454k), Brazil (US$203k), and Panama (US$191k).
Ciudad de México: US$51.5M, State with the Most International Purchases (2024)
India: US$34.3M, Main Commercial Origin (2024)
In 2024, the states with the highest international in Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were Ciudad de México (US$51.5M), Jalisco (US$33.2M), Estado de México (US$26.6M), Querétaro (US$2.4M), and Coahuila de Zaragoza (US$2.22M).
The countries with the most international sales to Mexico in 2024 were India (US$34.3M), China (US$27.2M), United States (US$15.1M), France (US$9.82M), and Germany (US$8.2M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were United States (US$1.4B), Portugal (US$1.23B), and Israel (US$1.2B). In the same year, the main importing countries for Medicaments (Excluding Goods of Heading 3002, 3005 or 3006) Consisting of Mixed together for Therapeutic or Prophylactic Uses, not in Measured Doses or put up for Retail were United States (US$1.36B), United Kingdom (US$1.31B), and Canada (US$881M).